Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07210554
PHASE3

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.

Official title: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-11-11

Completion Date

2028-05-08

Last Updated

2025-10-07

Healthy Volunteers

No

Interventions

BIOLOGICAL

Stapokibart injection

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China